QGENNYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
QIAGEN N.V.
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 20, 2026
$46.55+0.42 (+0.91%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- 24.0
- Dividend yield
- 0.54%
Ownership
Who owns Qiagen's shares
Held by institutions
–
Shares held, 13F filers
Institutional holders
–
Net institutional buying
–
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Wellington Management Company LLP | 23,291,538 | 6.50% | 13G (passive) | Jan 31, 2025 |
| BlackRock, Inc. | 20,678,987 | 10.00% | 13G (passive) | Jan 31, 2026 |
| Wellington Group Holdings LLP | 14,137,799 | 6.50% | 13G (passive) amendment | Dec 31, 2025 |
| Massachusetts Financial Services Company | 12,447,526 | 6.00% | 13G (passive) amendment | May 29, 2026 |
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Sackers Roland Officer | Aug 15, 2025 | 31,423 | $1.55M | Aug 15, 2025 | Performance Shares |
| Bernard Thierry Officer | Aug 15, 2025 | 25,000 | $1.22M | Aug 15, 2025 | RSU Award |
| Sackers Roland Officer | Aug 14, 2025 | 18,577 | $910.29K | Aug 14, 2025 | Performance Shares |
| Sackers Roland Officer | Aug 13, 2025 | 50,000 | $2.46M | Aug 13, 2025 | Performance Shares |
| Roland Sackers Officer | Sep 11, 2024 | 25,000 | $1.15M | Sep 11, 2024 | PERFORMANCE SHARES |
| Roland Sackers Officer | Aug 25, 2023 | 29,365 | $1.29M | Aug 25, 2023 | RETAIL PURCHASE |